OptiNose, Inc. (OPTN)
| Market Cap | 164.12M |
| Revenue (ttm) | 54.02M |
| Net Income (ttm) | -96.98M |
| Shares Out | 53.00M |
| EPS (ttm) | -1.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $3.12 |
| Previous Close | $3.09 |
| Change ($) | 0.03 |
| Change (%) | 0.97% |
| Day's Open | 3.07 |
| Day's Range | 3.01 - 3.19 |
| Day's Volume | 255,923 |
| 52-Week Range | 2.80 - 10.00 |
OptiNose (OPTN) delivered earnings and revenue surprises of 5.77% and 4.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of OptiNose (NASDAQ:OPTN) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 22.22% year over year to ($0.49), which beat the estimate of ($0....
Company reports first quarter total revenue of $12.0 million
OptiNose (NASDAQ:OPTN) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.
Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time
YARDLEY, Pa., April 27, 2021 /PRNewswire/ -- Optinose, (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced results...
YARDLEY, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that ...
OptiNose (OPTN) delivered earnings and revenue surprises of -2.22% and -10.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of OptiNose (NASDAQ:OPTN) decreased 0.8% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 20.69% over the past year to ($0.46), which were in...
OptiNose (NASDAQ:OPTN) unveils its next round of earnings this Wednesday, March 03. Here is Benzinga's everything-that-matters guide for the earnings announcement.
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conference Call and Webcast to be held March 3, 2021 at 8:00 a.m. Eastern Time
YARDLEY, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Opti N ose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announce...
YARDLEY, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Opti N ose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announce...
YARDLEY, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Bo...
After COVID-19 slowed their commercial launch, OPTN is doing an exceptional job selling Xhance. Q3 2020 revenues grew ~50% from Q2 & consensus FY2021 revenue estimates forecast 100% growth. Professional...
OptiNose (OPTN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
OptiNose, Inc. (OPTN) CEO Peter Miller on Q3 2020 Results - Earnings Call Transcript
Preliminary X HANCE Net Revenue G rowth of 78% C ompared to Third Quarter 2019 and 50% C ompared to Second Quarter 2020
YARDLEY, Pa., Sept. 29, 2020 /PRNewswire/ -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-...
YARDLEY, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...
OptiNose has not performed well since its IPO and comes under more pressure, caused by the coronavirus.
Some stock offerings dilute -- but not all.
Shares of Optinose Inc. OPTN, +2.49% plunged 23% in premarket trading Friday, after the specialty pharmaceuticals company, focused on ear, nose, throat and allergy patients, said its stock offering pric...
YARDLEY, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the pricin...
YARDLEY, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the commen...
OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2020 Results - Earnings Call Transcript
OptiNose (OPTN) delivered earnings and revenue surprises of -9.80% and -1.04%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
YARDLEY, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced th...
YARDLEY, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced it...
YARDLEY, Pa., July 08, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced th...
OptiNose Inc. (NASDAQ: OPTN) shares popped on Tuesday after the company announced that it is making a move toward fighting COVID-19 with its tech.
Company initiates development program using its EDS technology to deliver a nasal “antiseptic” intended to reduce illness and transmission of the COVID-19 virus Company initiates development program usi...
YARDLEY, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced th...
YARDLEY, Pa., June 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced th...
OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2020 Results - Earnings Call Transcript
OptiNose, Inc. (OPTN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Optinose, Inc. (OPTN) CEO Peter Miller on Q4 2019 Results - Earnings Call Transcript
OptiNose (OPTN) delivered earnings and revenue surprises of 13.43% and -11.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
YARDLEY, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...
YARDLEY, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...
A secondary offering resets the valuation of the ear, nose, and throat specialist.
Optinose, Inc.'s (OPTN) CEO Peter Miller on Q3 2019 Results - Earnings Call Transcript
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported the...
YARDLEY, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced t...
YARDLEY, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OptiNose , Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists,...
Company reiterates guidance for XHANCE net revenues for 2019 to be in the range of $29 - $34 million Company reiterates guidance for XHANCE net revenues for 2019 to be in the range of $29 - $34 million
About OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also d... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Oct 13, 2017 |
| CEO Peter Miller | Employees 204 |
| Stock Exchange NASDAQ | Ticker Symbol OPTN |
Financial Performance
In 2020, OptiNose's revenue was $49.12 million, an increase of 41.83% compared to the previous year's $34.63 million. Losses were -$99.79 million, -9.33% less than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for OptiNose stock is "Buy." The 12-month stock price forecast is 14.67, which is an increase of 370.19% from the latest price.